KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non Operating Income (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Non Operating Income for 17 consecutive years, with -$47.0 million as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income fell 611.18% year-over-year to -$47.0 million; the TTM value through Mar 2026 reached -$227.9 million, down 28.91%, while the annual FY2025 figure was -$178.4 million, 11.01% up from the prior year.
  • Non Operating Income hit -$47.0 million in Q1 2026 for Alnylam Pharmaceuticals, down from -$45.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $189.3 million in Q4 2022 and bottomed at -$147.9 million in Q3 2022.
  • Average Non Operating Income over 5 years is -$38.5 million, with a median of -$45.5 million recorded in 2025.
  • On a YoY basis, Non Operating Income climbed as much as 210.12% in 2022 and fell as far as 847.88% in 2022.
  • Alnylam Pharmaceuticals' Non Operating Income stood at $189.3 million in 2022, then crashed by 111.24% to -$21.3 million in 2023, then plummeted by 373.21% to -$100.7 million in 2024, then skyrocketed by 54.86% to -$45.5 million in 2025, then decreased by 3.36% to -$47.0 million in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$47.0 million, -$45.5 million, and -$129.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.